trending Market Intelligence /marketintelligence/en/news-insights/trending/8Z8kLqGP92JABjElBsBaKQ2 content esgSubNav
In This List

Antengene raises $120M to continue development of cancer drugs

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Antengene raises $120M to continue development of cancer drugs

Shanghai-based drug developer Antengene Corp. completed a $120 million series B financing, jointly led by Boyu Capital and FountainVest.

Celgene Corp., WuXi Corporate Venture Fund, Taikang, Qiming Venture Partners and TF Capital participated in the financing, Antengene said in a news release.

The company said it will use the funds to continue developing its lead programs ATG-008, a potential treatment for hematological malignancies and solid tumors, and ATG-010, also known as selinexor, a potential treatment for hepatitis B virus positive hepatocellular carcinoma.

Funds will also be used on Antengene's other clinical-stage assets, as well as expanding its pipeline, through internal research and development and external partnerships, and preparing the commercial launch of late-stage drug candidates.

Antengene is developing anti-cancer drug treatments for patients in China and Asia.